Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Veliparib, paclitaxel e carboplatino nel trattamento di pazienti con tumori solidi che sono metastatici o non possono essere rimossi chirurgicamente e con disfunzione epatica o renale

10 novembre 2026 aggiornato da: National Cancer Institute (NCI)

Uno studio iniziale di fase 1 su ABT-888 in combinazione con carboplatino e paclitaxel in pazienti con disfunzione epatica o renale e tumori solidi

This phase I trial studies the side effects and the best dose of veliparib when given together with paclitaxel and carboplatin in treating patients with solid tumors that are metastatic or cannot be removed by surgery and liver or kidney dysfunction. Veliparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as paclitaxel and carboplatin, work in different ways to stop the growth of tumor cells either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving veliparib together with paclitaxel and carboplatin may kill more tumor cells.

Panoramica dello studio

Descrizione dettagliata

PRIMARY OBJECTIVES:

I. To determine the pharmacokinetics and pharmacodynamics of ABT-888 (veliparib) in patients with varying degrees of renal or hepatic dysfunction.

II. To determine the maximum tolerated dose (MTD) of ABT-888 in combination with carboplatin and paclitaxel for patients with varying degrees of liver or kidney dysfunction.

III. To provide dosing recommendations for ABT-888 in combination with carboplatin and paclitaxel based on degree of hepatic and renal impairment.

SECONDARY OBJECTIVES:

I. To define the dose-limiting toxicity (DLT) and other toxicities associated with the use of this combination in patients with varying degrees of renal or hepatic dysfunction.

II. To evaluate the pharmacokinetic parameters of ABT-888, carboplatin, and paclitaxel when administered as a combination in patients with varying degrees of renal or hepatic dysfunction.

III. To evaluate the pharmacodynamic measurement of poly-ADP-ribosylated (PAR) and platinum adducts in tumor cells associated with the use of this combination in patients with varying degrees of renal or hepatic dysfunction.

OUTLINE: This is a dose-escalation study of veliparib.

Patients receive veliparib* orally (PO) twice daily (BID) on days 1-7 and paclitaxel intravenously (IV) over 3 hours and carboplatin IV over 30 minutes on day 3. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity.

NOTE: * All patients receive a single dose of veliparib PO on day -6 before course 1 (except patients with very severe renal dysfunction who receive veliparib on day -5 or -6 to coincide with a dialysis day).

After completion of study treatment, patients are followed up for 4 weeks.

Tipo di studio

Interventistico

Iscrizione (Effettivo)

94

Fase

  • Fase 1

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Luoghi di studio

    • California
      • Duarte, California, Stati Uniti, 91010
        • City of Hope Comprehensive Cancer Center
      • Sacramento, California, Stati Uniti, 95817
        • University of California Davis Comprehensive Cancer Center
      • South Pasadena, California, Stati Uniti, 91030
        • City of Hope South Pasadena
    • Florida
      • Tampa, Florida, Stati Uniti, 33612
        • Moffitt Cancer Center
    • Georgia
      • Atlanta, Georgia, Stati Uniti, 30322
        • Emory University Hospital/Winship Cancer Institute
    • Maryland
      • Baltimore, Maryland, Stati Uniti, 21287
        • Johns Hopkins University/Sidney Kimmel Cancer Center
    • Massachusetts
      • Boston, Massachusetts, Stati Uniti, 02215
        • Dana-Farber Cancer Institute
    • Michigan
      • Detroit, Michigan, Stati Uniti, 48201
        • Wayne State University/Karmanos Cancer Institute
    • New Jersey
      • New Brunswick, New Jersey, Stati Uniti, 08903
        • Rutgers Cancer Institute of New Jersey
    • New York
      • New York, New York, Stati Uniti, 10065
        • Memorial Sloan Kettering Cancer Center
      • The Bronx, New York, Stati Uniti, 10467
        • Montefiore Medical Center - Moses Campus
      • The Bronx, New York, Stati Uniti, 10461
        • Montefiore Medical Center-Weiler Hospital
    • Ohio
      • Cleveland, Ohio, Stati Uniti, 44106
        • Case Western Reserve University
    • Pennsylvania
      • Hershey, Pennsylvania, Stati Uniti, 17033-0850
        • Penn State Milton S Hershey Medical Center
      • Pittsburgh, Pennsylvania, Stati Uniti, 15232
        • UPMC Hillman Cancer Center
    • Texas
      • Houston, Texas, Stati Uniti, 77030
        • UT MD Anderson Cancer Center
    • Wisconsin
      • Madison, Wisconsin, Stati Uniti, 53792
        • University of Wisconsin Carbone Cancer Center - University Hospital

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

18 anni e precedenti (Adulto, Adulto più anziano)

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Descrizione

Inclusion Criteria:

  • Patients must have histologically confirmed malignancy that is radiologically evaluable and metastatic or unresectable, for which standard curative or palliative measures do not exist or are no longer effective, and for which there is expectation of response to the combination of carboplatin/paclitaxel (i.e., lung, ovarian, breast, melanoma, head and neck, endometrial, urothelial, testicular, esophageal, carcinoma of unknown primary); for indications not listed, eligibility based on disease must be verified by the principal investigator before they are considered
  • Eastern Cooperative Oncology Group (ECOG) performance status =< 2 (Karnofsky >= 60%)
  • Life expectancy of greater than 12 weeks
  • Absolute neutrophil count >= 1,500/mcL
  • Platelets >= 100,000/mcL
  • Hemoglobin >= 8.0 g/dL
  • Patients with all degrees of renal dysfunction are allowed including patients on hemodialysis; patients with mild to severe hepatic dysfunction are allowed as defined below:
  • Total bilirubin =< 5 x upper limit of normal (ULN)
  • Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 10 x ULN
  • For patients with a recently placed biliary stent, patients should have consistent results within a hepatic group from two laboratory readings within 3 days apart, taken at least 10 days following biliary stent placement; for patients with a biliary stent placed over 2 months ago, no obstruction or blockage can have occurred within the last 2 months
  • Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation; should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately
  • Ability to understand and the willingness to sign a written informed consent document

Exclusion Criteria:

  • Patients who have had chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or those whose adverse event due to agents administered more than 4 weeks earlier have not resolved or stabilized; patients who have been administered ABT-888 as part of a single or combination, phase 0 or I study, should not necessarily be excluded from participating in this study solely because of receiving prior ABT-888
  • Patients may not be receiving any other investigational agents
  • History of allergic reactions attributed to compounds of similar chemical or biologic composition to ABT-888 or other agents used in study
  • Peripheral neuropathy of severity greater than grade 1
  • Inability to take oral medications on a continuous basis
  • Evidence of bleeding diathesis
  • Patients with central nervous system (CNS) metastases must be stable after therapy for CNS metastases (such as surgery, radiotherapy or stereotactic radiosurgery) for at least 3 months and must be off steroid treatment prior to study enrollment
  • Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
  • Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with ABT-888; these potential risks may also apply to other agents used in this study
  • Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible; however, HIV-positive patients without an acquired immune deficiency syndrome (AIDS)-defining diagnosis who are not receiving agents with the potential for pharmacokinetic (PK) interactions with ABT-888 may be eligible
  • Patients with both hepatic and renal dysfunction will also be excluded
  • Patients who received and progressed on the combination of carboplatin/paclitaxel will not be eligible
  • Active seizure or history of seizure disorder

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Trattamento
  • Assegnazione: N / A
  • Modello interventistico: Assegnazione di gruppo singolo
  • Mascheramento: Nessuno (etichetta aperta)

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Sperimentale: Treatment (veliparib, paclitaxel, carboplatin)

Patients receive veliparib* PO BID on days 1-7 and paclitaxel IV over 3 hours and carboplatin IV over 30 minutes on day 3. Courses repeat every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity.

NOTE: * All patients receive a single dose of veliparib PO on day -6 before course 1 (except patients with very severe renal dysfunction who receive veliparib on day -5 or -6 to coincide with a dialysis day).

Given IV

Altri nomi:
  • Blastocarb
  • Carboplat
  • Carboplatino Hexal
  • Carboplatino
  • Carbosina
  • Carbosol
  • Carbotec
  • CBDCA
  • Displata
  • Ercar
  • JM-8
  • Nealorin
  • Novoplatino
  • Paraplatino
  • Paraplatino AQ
  • Platino
  • Ribocarbonio
  • JM8

Given IV

Altri nomi:
  • Tassolo
  • Anzatax
  • Asotax
  • Bristaxolo
  • Praxel
  • Taxol Konzentrat

Correlative studies

Given PO

Altri nomi:
  • ABT-888
  • Inibitore PARP-1 ABT-888
  • 888 circa
  • ABT888

Correlative studies

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
MTD di veliparib in combinazione con carboplatino e paclitaxel, determinato in base all'incidenza di DLT come graduato utilizzando i Common Terminology Criteria for Adverse Events (NCI CTCAE) del National Cancer Institute versione (v) 4.0
Lasso di tempo: 21 giorni
21 giorni
PK parameters of veliparib
Lasso di tempo: Day -6 and 3 of course 1 after veliparib dosing

Standard quantitative and graphical statistical summaries of the derived PK parameters (e.g. area under curve and clearance) will be produced for each organ function cohort. The effect of dysfunction on pharmacokinetics will be explored by comparing each pharmacokinetic parameter across all cohorts using one-way analysis (analysis of variance) or Kruskal-Wallis test. The level of each protein will be compared between responders and non-responders using the Wilcoxon signed rank test.

Day -6 and 3 of course 1 after veliparib dosing

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Incidence of toxicities as assessed by NCI CTCAE v4.0
Lasso di tempo: Up to 4 weeks after completion of study treatment

The maximum grade of toxicity for each category of interest will be recorded for each patient and the summary results will be tabulated by category, grade and dose level. Severe and life-threatening toxicities and adverse event-related deaths (>= grade 3) will be described on a patient-by-patient basis and will include any relevant baseline data.

Up to 4 weeks after completion of study treatment
Response rate as assessed by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1
Lasso di tempo: Up to 4 weeks after completion of study treatment

Responses will be tabulated by disease diagnosis and by dose level. 95% confidence limits will also be reported on the response rates.

Up to 4 weeks after completion of study treatment
Incidence of stable disease as assessed by RECIST version 1.1
Lasso di tempo: Up to 4 weeks after completion of study treatment

Incidence of stable disease will be tabulated by disease diagnosis and by dose level.

Up to 4 weeks after completion of study treatment
Time to progression
Lasso di tempo: Up to 4 weeks after completion of study treatment

Displayed for all patients and for patients who have responded; no formal statistical analysis is planned.

Up to 4 weeks after completion of study treatment

Altre misure di risultato

Misura del risultato
Misura Descrizione
Lasso di tempo
Change in PAR levels
Lasso di tempo: Baseline to up to 4 weeks

Descriptive statistics (mean, standard deviation, median, range) for measurements of PAR levels will provided with 95% confidence intervals (CIs). When sample size permits, a formal statistical test using the Wilcoxon signed rank test will be used to compare the post treatment PAR levels to the baseline levels. When feasible, the level will be compared between responders and non-responders using the Wilcoxon signed rank test.

Baseline to up to 4 weeks
Change in gamma-H2AX levels
Lasso di tempo: Baseline to up to 4 weeks

Descriptive statistics (mean, standard deviation, median, range) for measurements of gamma-H2AX levels will provided with 95% CIs. When sample size permits, a formal statistical test using the Wilcoxon signed rank test will be used to compare the post treatment PAR levels to the baseline levels. When feasible, the level will be compared between responders and non-responders using the Wilcoxon signed rank test.

Baseline to up to 4 weeks

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Investigatori

  • Investigatore principale: Hussein A Tawbi, University of Pittsburgh Cancer Institute (UPCI)

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

20 giugno 2011

Completamento primario (Effettivo)

10 novembre 2017

Completamento dello studio (Stimato)

3 marzo 2027

Date di iscrizione allo studio

Primo inviato

2 giugno 2011

Primo inviato che soddisfa i criteri di controllo qualità

2 giugno 2011

Primo Inserito (Stimato)

3 giugno 2011

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

12 novembre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

10 novembre 2026

Ultimo verificato

1 settembre 2026

Maggiori informazioni

Termini relativi a questo studio

Termini MeSH pertinenti aggiuntivi

Altri numeri di identificazione dello studio

  • NCI-2011-02500
  • U01CA070095 (Sovvenzione/contratto NIH degli Stati Uniti)
  • UM1CA186691 (Sovvenzione/contratto NIH degli Stati Uniti)
  • UM1CA186716 (Sovvenzione/contratto NIH degli Stati Uniti)
  • U01CA099168 (Sovvenzione/contratto NIH degli Stati Uniti)
  • U01CA062502 (Sovvenzione/contratto NIH degli Stati Uniti)
  • U01CA062505 (Sovvenzione/contratto NIH degli Stati Uniti)
  • U01CA062490 (Sovvenzione/contratto NIH degli Stati Uniti)
  • U01CA069856 (Sovvenzione/contratto NIH degli Stati Uniti)
  • UM1CA186690 (Sovvenzione/contratto NIH degli Stati Uniti)
  • UM1CA186717 (Sovvenzione/contratto NIH degli Stati Uniti)
  • UM1CA186709 (Sovvenzione/contratto NIH degli Stati Uniti)
  • N01CM00100 (Sovvenzione/contratto NIH degli Stati Uniti)
  • P30CA047904 (Sovvenzione/contratto NIH degli Stati Uniti)
  • NCI-2011-02500 (Identificatore di registro: CTRP (Clinical Trial Reporting Program))
  • CDR0000700997
  • UPCI 10-115
  • UPCI-10-115
  • 8808 (Altro identificatore: CTEP)
  • 8808 (Altro identificatore: UPMC Hillman Cancer Center)

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Sottoscrivi